TB-500 Peptide Injury Protocol: Dosing, Timing, and What the Research Shows

TB-500 (Thymosin Beta-4) has become one of the most researched peptides in the recovery community. Unlike many peptides that work primarily through growth hormone pathways, TB-500 promotes cell migration, angiogenesis, and actin regulation — processes that are fundamental to how tissue heals at a cellular level.

This guide covers the evidence-based approach to using TB-500 for injury recovery, including loading protocol, maintenance dosing, and realistic healing timelines based on injury type.

How TB-500 Works

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide found in high concentrations in wound fluid and blood platelets. Its primary mechanism involves:

Actin regulation — TB-500 sequesters G-actin (globular actin), which is the monomer form of actin that cells need to build cellular scaffolding. By binding to actin, TB-500 helps regulate cell migration and tissue remodeling.

Angiogenesis — TB-500 promotes the formation of new blood vessels, which is critical for delivering oxygen and nutrients to injured tissue. Poor vascular supply is one of the main reasons tendons and ligaments heal slowly.

Anti-inflammatory effects — TB-500 has documented anti-inflammatory properties at the site of injury, which can help manage the chronic inflammation that impairs healing in overuse injuries.

Stem cell recruitment — Research suggests TB-500 promotes migration of progenitor cells to injury sites, which supports regeneration rather than just scar tissue formation.

The Standard Injury Protocol

The most commonly used and well-documented protocol for injury recovery:

Loading Phase (Weeks 1–4)

Maintenance Phase (Weeks 5–12)

Recovery Monitoring Phase (Weeks 12+)

Injection Timing and Administration

Injection site: Most protocols use subcutaneous injection in the abdominal region or near the injury site. Some practitioners report improved results with local injection near the injury, though systemic subcutaneous injection is more common and well-documented.

Timing relative to training: TB-500 is not acutely performance-enhancing, so timing relative to workouts is not critical. Most users inject on rest days to simplify tracking.

Reconstitution: TB-500 powder is reconstituted with bacteriostatic water. Use 1–2 mL of BAC water per vial and store refrigerated. See our full reconstitution guide for step-by-step instructions.

Healing Timelines by Injury Type

Research and user data suggest TB-500 accelerates healing — but does not eliminate it. Realistic timelines:

Tendon Injuries (Achilles, Patellar, Rotator Cuff)

Muscle Tears and Strains

Ligament Injuries (ACL, MCL)

Joint Inflammation and Cartilage

Stacking TB-500 With BPC-157

TB-500 and BPC-157 are the two most commonly stacked recovery peptides because they work through different mechanisms:

Together, they address different aspects of the healing cascade. See our TB-500 and BPC-157 stack guide for protocol details.

What the Research Actually Shows

Human clinical trials on TB-500 specifically are limited. Most robust research is preclinical:

The human evidence base is growing but remains preliminary for musculoskeletal applications. The strong preclinical data and safety profile in early human trials explain why the recovery community has adopted it widely.

Important Safety Considerations

TB-500 has shown a favorable safety profile in research to date, but:

Practical Tips for Better Results

1. Address the root cause — TB-500 accelerates healing but won't fix biomechanical problems that caused the injury
2. Maintain some movement — Immobilization during recovery is counterproductive. Light, pain-free movement during TB-500 protocol supports proper tissue remodeling
3. Nutrition supports healing — Adequate protein (1.6–2g/kg bodyweight), collagen precursors (vitamin C + glycine), and zinc all support the healing processes TB-500 initiates
4. Track progress — Keep notes on pain levels, range of motion, and functional capacity weekly

Where These Protocol Numbers Actually Come From

It's worth being direct about something the loading/maintenance framework above glosses over: the 2–2.5 mg, twice-weekly loading dose didn't come out of a human dose-ranging clinical trial. No such trial exists for the injectable TB-500 fragment — see our human clinical trials guide for what has and hasn't actually been tested in humans. The numbers in wide circulation trace back to a mix of animal-study dose scaling (adjusted, often loosely, from mg/kg doses used in rodent injury models) and years of accumulated community reporting on what researchers say worked for them.

That doesn't mean the protocol is arbitrary — it's converged on a fairly narrow range across independent sources, which is at least a signal of rough consensus. But "consensus among self-reporting researchers" and "dose established by a controlled clinical trial" are different categories of evidence, and treating the former as the latter overstates what's actually known. Anyone designing a research protocol around these numbers should understand they're inheriting community-derived estimates, not a validated dosing curve.

What If There's No Improvement After 4 Weeks?

This comes up often enough to address directly: a lack of noticeable change by the end of the loading phase doesn't necessarily mean the protocol failed. Tissue remodeling — as opposed to the initial cell migration and angiogenesis TB-500's mechanisms are thought to support — happens on a slower timeline than most loading phases run. For structural injuries (partial tendon tears, ligament sprains), four weeks is often still early in the biological repair window, not a checkpoint where results should already be obvious. That said, if pain or dysfunction is worsening rather than plateauing, that's a signal to stop and get a clinical evaluation, not to escalate the dose — TB-500 research doesn't support pushing through worsening symptoms, and a structural injury that's getting worse needs imaging and a clinician, not a longer peptide cycle.

Frequently Asked Questions

Are the standard TB-500 protocol doses backed by clinical research?

No. The commonly cited 2–2.5 mg loading protocol is derived from animal-study dose scaling and years of community-reported outcomes, not a human clinical dose-ranging trial. No such trial exists for the injectable TB-500 fragment. Treat the numbers as a converged community estimate, not a validated clinical dose.

Can the loading dose be split into smaller, more frequent injections instead of two larger ones?

Some researchers do this on the theory that more frequent, smaller doses maintain steadier tissue levels, but there's no comparative research testing split-dosing against the standard twice-weekly protocol specifically for injury recovery. Given TB-500's reported multi-day half-life (see our half-life and timing guide), the practical difference between splitting and not splitting the same weekly total is unclear.

Does a more severe injury justify a longer loading phase?

This is a common adjustment in community protocols — extending the 4-week loading phase for injuries involving more extensive tissue damage — but it's an inference based on the general principle that more damaged tissue needs a longer proliferative healing window, not a finding from injury-severity-specific dosing research.

How is protocol design for TB-500 different from BPC-157?

The core difference is systemic versus local action. TB-500's protocol design doesn't depend on injection location because it's understood to act systemically, while BPC-157 protocols often specify injecting near the injury site. See our TB-500 and BPC-157 stack guide for how the two get combined in practice.

Is it necessary to cycle off TB-500 between protocols?

Most community protocols recommend a break of several weeks between full cycles, though this is precautionary rather than based on documented evidence of tolerance or desensitization. There's no published research establishing what happens with truly continuous, uninterrupted use.

Summary

TB-500 is one of the most mechanistically well-understood recovery peptides. The standard injury protocol — 2.5 mg 2x/week for 4 weeks loading, followed by 2.5 mg 1x/week maintenance — is based on preclinical dosing models and user-validated anecdotal evidence, not a human clinical dose-finding trial.

For tendon and muscle injuries, users consistently report accelerated return to function. The combination with BPC-157 represents the current evidence-based best practice for comprehensive soft tissue recovery.

Always source from reputable suppliers with third-party testing, and consult a knowledgeable physician before starting any peptide protocol.